乐普生物临床前 ADC 重磅出海

国际金融报
23 Jan

近日,乐普生物宣布,与海外生物制药公司ArriVent BioPharma, Inc.就针对消化道癌的潜在同类最佳抗体偶联药物MRG007达成全球独家许可协议。2025年国产ADC出海再添一员。 潜在“best-in-class”  根据协议,乐普生物授予ArriVent在大中华区(包括中国内地、中国香港、中国澳门和中国台湾)以外地区开发、制造和商业化MRG007的全球独家许可。  乐普生物将获得...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10